Delivery Order SPE2DB20D3103-SPE2DB25FP9Q5
- Not listed
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $2,343.59 on August 18, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectors. This is a firm fixed price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of September 9, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a...
- The Defense Logistics Agency awarded a $35,153.85 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectors. The contract, which is non-set-aside and competitively awarded, carries an ultimate completion date of September 3, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors, valued at $2,343.59 with a firm fixed price structure. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999 through December 2026. The award carries no set-aside designation and was competitively...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,343.59 to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 ml pen injectors, with an ultimate completion date of September 12, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a single delivery order under AmerisourceBergen's larger prime contract vehicle with DLA. The pharmaceutical products will be delivered to AmerisourceBergen's corporate headquarters location in...
- The Defense Logistics Agency awarded a $4,687.18 delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Tezspire 210 mg/1.91 mL pen auto-injectors. This competitively awarded, firm fixed-price contract with an ultimate completion date of September 3, 2025, represents a child order under AmerisourceBergen's larger pharmaceutical supply agreement. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a $4,687.18 delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectables. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion deadline of August 28, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order is a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $4,687.18 to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors. The contract carries a firm fixed price structure with no set-aside designation, indicating competitive award status. Performance will be completed by September 5, 2025, with all work performed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Tezspire 210 mg/1.91 mL pen auto-injectors. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $7,030.77 and is scheduled for completion by September 12, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a single transaction within...
- The Defense Logistics Agency awarded a $18,748.72 delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for TEZSPIRE 210 mg/1.91 mL pen injectors, with a completion date of September 3, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a child order under a larger contract vehicle, this delivery order...
- The Defense Logistics Agency awarded a $28,123.08 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors. The contract, with an ultimate completion date of September 10, 2025, represents a non-set-aside competitive award executed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FP9Q5Delivery Order
The Defense Logistics Agency awarded a $4,687.18 delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors with an ultimate completion date of September 11, 2025. This competitive award was issued under a firm fixed-price contract structure with no set-aside designation. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and running through December 2026. As a major pharmaceutical distributor, AmerisourceBergen serves as a critical vendor for federal medical procurement, supplying a comprehensive range of pharmaceutical products and medical supplies to support military and veteran healthcare systems. Tezspire is a specialized biologic medication used in the treatment of moderate to severe asthma, reflecting the breadth of therapeutic domains covered under the company's prime vendor arrangement with the Defense Logistics Agency.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.7k | 8/20/25 |